A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Asparaginase-like protein 1 as a prognostic tissue biomarker in clinicopathologically and molecularly characterized endometrial cancer
Tekijät: Loukovaara, Mikko J.; Huvila, Jutta K.; Pasanen, Annukka M.; Bützow, Ralf C.
Kustantaja: Elsevier
Julkaisuvuosi: 2024
Journal: European Journal of Obstetrics and Gynecology and Reproductive Biology
Tietokannassa oleva lehden nimi: European Journal of Obstetrics & Gynecology and Reproductive Biology
Vuosikerta: 300
Aloitussivu: 23
Lopetussivu: 28
ISSN: 0301-2115
eISSN: 1872-7654
DOI: https://doi.org/10.1016/j.ejogrb.2024.07.007
Verkko-osoite: https://doi.org/10.1016/j.ejogrb.2024.07.007
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/457113036
Objective Prognostic stratification of endometrial cancer involves the assessment of stage, uterine risk factors, and molecular classification. This process can be further refined through annotation of prognostic biomarkers, notably L1 cell adhesion molecule (L1CAM) and hormonal receptors. Loss of asparaginase-like protein 1 (ASRGL1) has been shown to correlate with poor outcome in endometrial cancer. Our objective was to assess prognostication of endometrial cancer by ASRGL1 in conjunction with other available methodologies. Study Design This was a retrospective study of patients who underwent primary treatment at a single tertiary center. Tumors were molecularly classified by the Proactive Molecular Risk Classifier for Endometrial Cancer. Expression of ASRGL1, L1CAM, estrogen receptor, and progesterone receptor was determined by immunohistochemistry. ASRGL1 expression intensity was scored into four classes. Results In a cohort of 775 patients, monitored for a median time of 81 months, ASRGL1 expression intensity was related to improved disease-specific survival in a dose-dependent manner (P < 0.001). Low expression levels were associated with stage II–IV disease and presence of uterine factors, i.e. high grade, lymphovascular space invasion, and deep myometrial invasion (P < 0.001 for all). Among the molecular subgroups, low expression was most prevalent in p53 abnormal carcinomas (P < 0.001). Low ASRGL1 was associated with positive L1CAM expression and negative estrogen and progesterone receptor expression (P < 0.001 for all). After adjustment for stage and uterine factors, strong ASRGL1 staining intensity was associated with a lower risk for cancer-related deaths (hazard ratio 0.56, 95 % confidence interval 0.32–0.97; P = 0.038). ASRGL1 was not associated with the outcome when adjusted for stage, molecular subgroups, L1CAM, and hormonal receptors. When analyzed separately within the different molecular subgroups, ASRGL1 showed an association with disease-specific survival specifically in “no specific molecular profile” subtype carcinomas (P < 0.001). However, this association became nonsignificant upon controlling for confounders. Conclusions Low ASRGL1 expression intensity correlates with poor survival in endometrial cancer. ASRGL1 contributes to more accurate prognostication when controlled for stage and uterine factors. However, when adjusted for stage and other biomarkers, including molecular subgroups, ASRGL1 does not improve prognostic stratification.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
Julkaisussa olevat rahoitustiedot:
This work was funded by Helsinki University Hospital research funds (TYH2020302) and Cancer Foundation Finland (WBS4708719).
